# OnCo record extrahepatic-cholangiocarcinoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "extrahepatic-cholangiocarcinoma" ;
  schema:name "Extrahepatic cholangiocarcinoma (perihilar and distal)"@en ;
  schema:alternateName "Perihilar cholangiocarcinoma"@en, "Klatskin tumour"@en, "Hilar cholangiocarcinoma"@en, "Distal cholangiocarcinoma"@en, "Common bile duct cancer"@en, "eCCA"@en ;
  schema:description "Extrahepatic cholangiocarcinoma blocks the main bile ducts outside the liver and shows itself as jaundice. Perihilar tumours need part of the liver removed with the duct and distal tumours a Whipple operation; where surgery is impossible, stenting relieves the jaundice and chemotherapy with immunotherapy follows, with HER2-directed antibodies for the one in six tumours that carry that target."@en ;
  schema:url <https://onco.cc/cancers/extrahepatic-cholangiocarcinoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Klatskin_tumor> ;
  schema:citation <https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200015>, <https://pubmed.ncbi.nlm.nih.gov/37276871/>, <https://en.wikipedia.org/wiki/Klatskin_tumor> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/trials/herizon-btc-302/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/technologies/liver-transplant-oncology/> ;
  onco:standardOfCare <https://onco.cc/technologies/mri/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/terms/endoscopy/>, <https://onco.cc/technologies/biliary-stenting-drainage/>, <https://onco.cc/terms/ca19-9/>, <https://onco.cc/terms/hepatectomy/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/trials/bilcap/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/terms/whipple/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/trials/bilcap/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/technologies/liver-transplant-oncology/>, <https://onco.cc/trials/topaz-1/>, <https://onco.cc/trials/keynote-966/>, <https://onco.cc/trials/abc-02/>, <https://onco.cc/drugs/gemcitabine-cisplatin/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/pairings/gemcis-plus-io-btc/>, <https://onco.cc/drugs/zanidatamab/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/targets/her2/>, <https://onco.cc/trials/herizon-btc-302/>, <https://onco.cc/drugs/folfox/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/terms/msi/>, <https://onco.cc/drugs/dabrafenib-trametinib/> .